FGL1抗体

+ +

•  

   

     Gel: 15%SDS-PAGE, Lysate: 40 μg, Lane: Human fetal liver tissue, Primary antibody: P07294(FGL1 Antibody) at dilution 1/1050, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 2 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07294(FGL1 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

**Background of FGL1 Antibody**

Fibrinogen-like protein 1 (FGL1), a member of the fibrinogen-related protein family, is a secreted glycoprotein implicated in immune regulation and cancer progression. It gained attention as a functional ligand of lymphocyte-activation gene 3 (LAG-3), an inhibitory immune checkpoint receptor expressed on T cells. FGL1-LAG-3 interaction suppresses T cell activation, enabling tumor immune evasion. Overexpression of FGL1 in cancers (e.g., liver, lung, and pancreatic) correlates with poor prognosis, suggesting its role as a therapeutic target.

FGL1 antibodies are designed to block this interaction, restoring anti-tumor T cell activity. Preclinical studies demonstrate that FGL1 antibodies enhance immune responses and inhibit tumor growth in murine models, particularly in tumors resistant to PD-1/PD-L1 blockade. These findings position FGL1 as a promising complementary target in cancer immunotherapy.

Beyond oncology, FGL1 is involved in metabolic and inflammatory processes, such as liver regeneration and viral hepatitis. Structurally, FGL1 contains a fibrinogen-like domain and forms disulfide-linked homodimers. Its expression is elevated in certain tissues under pathological conditions, making it a potential biomarker. Current research focuses on optimizing FGL1 antibody specificity and evaluating safety in clinical trials, aiming to expand immune checkpoint therapy options.